Table 4.
Baseline characteristics of included patients in the validation cohort.
| Variables | Overall (N=420) | Short S-C group (N=210) | Long S-C group (N=210) | P value |
|---|---|---|---|---|
| Median (range) or Frequency (percentage) | Median (range) or Frequency (percentage) | Median (range) or Frequency (percentage) | ||
| Age (years) | 52.00 (16.00–82.00) | 53.50 (16.00–81.00) | 52.00 (18.00–82.00) | 0.140 |
| Female | 180 (42.9%) | 90 (42.9%) | 90 (42.9%) | 1.000 |
| BMI (kg/m2) | 24.25 (16.00–51.40) | 24.20 (16.00–33.00) | 24.70 (16.10–51.40) | 0.223 |
| Weight (kg) | 67.50 (40.00–143.00) | 67.75 (40.00–101.00) | 67.50 (40.00–143.00) | 0.499 |
| Height (m) | 1.70 (1.44–1.90) | 1.70 (1.50–1.90) | 1.70 (1.44–1.90) | 0.772 |
| History of colonoscopy | 187 (44.5%) | 103 (49.0%) | 84 (40.0%) | 0.062 |
| History of abdominal surgery | 121 (28.8%) | 50 (23.8%) | 71 (33.8%) | 0.024 |
| Indications for colonoscopy | ||||
| Abdominal pain/discomfort | 127 (30.2%) | 55 (26.2%) | 72 (34.3%) | 0.071 |
| Bloating | 19 (4.5%) | 10 (4.8%) | 9 (4.3%) | 0.814 |
| Abnormal defecation | 258 (61.4%) | 121 (57.6%) | 137 (65.2%) | 0.109 |
| Polyp | 32 (7.6%) | 27 (12.9%) | 5 (2.4%) | <0.001 |
| Health checkup | 68 (16.2%) | 39 (18.6%) | 29 (13.8%) | 0.185 |
| Others | 8 (1.9%) | 4 (1.9%) | 4 (1.9%) | 1.000 |
| Run-way time | 6.68 (3.15–12.27) | 5.58 (3.15–10.29) | 8.55 (6.10–12.27) | <0.001 |
| Colonoscopy started in the morning | 295 (70.2%) | 203 (96.7%) | 92 (43.8%) | <0.001 |
| Significant bubbles | 2 (0.5%) | 1 (0.5%) | 1 (0.5%) | 1.000 |
| Adverse event | ||||
| Nausea | 16 (3.8%) | 10 (4.8%) | 6 (2.9%) | 0.308 |
| Vomiting | 3 (0.7%) | 3 (1.4%) | 0 (0%) | 0.247 |
| Abdominal pain | 0 (0%) | 0 (0%) | 0 (0%) | – |
| Bloating | 0 (0%) | 0 (0%) | 0 (0%) | – |
S-C – time interval between oral simethicone and the start of colonoscopy; BMI – body mass index.